Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-dose food effect and drug–drug interaction study of E7090 with rabeprazole or rifampin in healthy subjects
jRCT2031200214Phase 1Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tasurgratinib in cholangiocarcinoma (CCA), sponsored by Eisai Co., Ltd. Primary endpoint: Plasma concentration of compound(s). Started Oct 2020; status: active, not recruiting.
02
Drugs
tasurgratinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on jRCT2031200214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200214.